scholarly article | Q13442814 |
P356 | DOI | 10.1007/S10741-018-9703-2 |
P698 | PubMed publication ID | 29704192 |
P50 | author | Leonardo Roever | Q52097086 |
P2093 | author name string | Marconi Abreu | |
Andre Rodrigues Duraes | |||
Joaquim Silva Custodio | |||
Natalia Albuquerque Rocha | |||
P2860 | cites work | Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats | Q24563606 |
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial | Q27301948 | ||
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 | ||
Alogliptin after acute coronary syndrome in patients with type 2 diabetes | Q28297690 | ||
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association | Q30238784 | ||
Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association | Q30249059 | ||
Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans | Q33356608 | ||
The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota | Q33825297 | ||
Heart failure in the diabetic population - pathophysiology, diagnosis and management | Q33935375 | ||
SGLT2 mediates glucose reabsorption in the early proximal tubule. | Q34457264 | ||
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | Q34540403 | ||
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes | Q34670462 | ||
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib | Q34677347 | ||
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial | Q34985342 | ||
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 | ||
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus | Q36622125 | ||
Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. | Q36654675 | ||
Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs | Q36783681 | ||
Epidemiology and aetiology of heart failure | Q36905978 | ||
Metabolic dysfunction in diabetic cardiomyopathy | Q36930481 | ||
Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options | Q37055775 | ||
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial | Q37106527 | ||
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial | Q37302078 | ||
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes | Q37532095 | ||
The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. | Q38262227 | ||
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cot | Q38376619 | ||
Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes | Q38723450 | ||
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q38729780 | ||
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. | Q38822669 | ||
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. | Q38912082 | ||
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition | Q39035951 | ||
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms | Q39318765 | ||
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome | Q41078909 | ||
Diabetes and cardiovascular disease. The Framingham study | Q41509493 | ||
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. | Q41895967 | ||
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial | Q43804231 | ||
Intracellular Na(+) concentration is elevated in heart failure but Na/K pump function is unchanged | Q44009242 | ||
The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality | Q44520653 | ||
Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure | Q46707691 | ||
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes | Q46818617 | ||
Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? | Q47384272 | ||
Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes | Q48126574 | ||
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial | Q48184186 | ||
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. | Q50955035 | ||
EMPA-REG OUTCOME: The Cardiologist's Point of View. | Q50991867 | ||
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. | Q51304272 | ||
Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes. | Q51355578 | ||
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. | Q51382208 | ||
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. | Q51707689 | ||
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. | Q51832630 | ||
Diabetes Mellitus and Heart Failure. | Q52867555 | ||
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors | Q63071417 | ||
P433 | issue | 3 | |
P304 | page(s) | 409-418 | |
P577 | publication date | 2018-05-01 | |
P1433 | published in | Heart Failure Reviews | Q2167497 |
P1476 | title | SGLT2 inhibition and heart failure-current concepts | |
P478 | volume | 23 |